KM 819

Drug Profile

KM 819

Alternative Names: KM-819; KR-33493

Latest Information Update: 24 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chungnam National University; Korea Research Institute of Chemical Technology
  • Developer Chungnam National University; Kainos Medicines; Korea Research Institute of Chemical Technology
  • Class Antiparkinsonians
  • Mechanism of Action Apoptosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Parkinson's disease (In volunteers) in South Korea (PO) (NCT03022799)
  • 13 Apr 2016 Preclinical trials in Parkinson's disease in South Korea (PO) before April 2016
  • 13 Apr 2016 Korea FDA approves IND application for initiation of a phase I trial of KR 33493 in Parkinson's disease (Kainos Medicine pipeline, April 2016) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top